What is he best known for?
The fields of study he is best known for:
- Cancer
- Internal medicine
- Surgery
Michel Ducreux mostly deals with Internal medicine, Surgery, Colorectal cancer, Oncology and Gastroenterology.
Oxaliplatin, Chemotherapy, Cancer, Performance status and Prospective cohort study are subfields of Internal medicine in which his conducts study.
His biological study spans a wide range of topics, including Confidence interval and Hazard ratio.
His study in Colorectal cancer is interdisciplinary in nature, drawing from both Survival rate, Fluorouracil and Metastasis.
The Oncology study combines topics in areas such as Bevacizumab, Pancreatic cancer and FOLFIRI.
His work in the fields of Carcinoid syndrome overlaps with other areas such as Lanreotide.
His most cited work include:
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer (4092 citations)
- KRAS Mutation Status Is Predictive of Response to Cetuximab Therapy in Colorectal Cancer (1905 citations)
- ESMO consensus guidelines for the management of patients with metastatic colorectal cancer (1308 citations)
What are the main themes of his work throughout his whole career to date?
Internal medicine, Oncology, Colorectal cancer, Chemotherapy and Surgery are his primary areas of study.
His Internal medicine study frequently draws connections to other fields, such as Gastroenterology.
His study focuses on the intersection of Gastroenterology and fields such as Fluorouracil with connections in the field of Antimetabolite.
His studies examine the connections between Oncology and genetics, as well as such issues in Clinical trial, with regards to Randomized controlled trial.
His research investigates the link between Colorectal cancer and topics such as Metastasis that cross with problems in Radiology.
His research brings together the fields of Carcinoma and Surgery.
He most often published in these fields:
- Internal medicine (66.15%)
- Oncology (40.28%)
- Colorectal cancer (30.03%)
What were the highlights of his more recent work (between 2015-2021)?
- Internal medicine (66.15%)
- Oncology (40.28%)
- Colorectal cancer (30.03%)
In recent papers he was focusing on the following fields of study:
His primary areas of investigation include Internal medicine, Oncology, Colorectal cancer, Cancer and Chemotherapy.
His study in Gastroenterology extends to Internal medicine with its themes.
Michel Ducreux combines subjects such as Pancreatic cancer, Sorafenib, Randomized controlled trial, Gemcitabine and Locally advanced with his study of Oncology.
His Colorectal cancer research incorporates themes from Observational study, Clinical endpoint, Surgery and Cohort.
His Cancer study combines topics in areas such as Cancer research, Clinical trial, Intensive care medicine, Vaccination and Radiation therapy.
His Chemotherapy research includes themes of Surgical oncology, Survival rate, Toxicity, Prospective cohort study and Immunotherapy.
Between 2015 and 2021, his most popular works were:
- ESMO consensus guidelines for the management of patients with metastatic colorectal cancer (1308 citations)
- Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma (529 citations)
- Local Treatment of Unresectable Colorectal Liver Metastases: Results of a Randomized Phase II Trial (213 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Surgery
Michel Ducreux focuses on Internal medicine, Oncology, Surgery, Gastroenterology and Colorectal cancer.
His Bevacizumab, Cancer, Clinical trial and Oxaliplatin study, which is part of a larger body of work in Internal medicine, is frequently linked to In patient, bridging the gap between disciplines.
His Oncology research includes elements of Hepatocellular carcinoma, Targeted therapy, Gemcitabine and Endocrine system.
The various areas that Michel Ducreux examines in his Surgery study include Gastrointestinal cancer and General surgery.
His work carried out in the field of Gastroenterology brings together such families of science as Progression-free survival, Placebo, Ramucirumab, Hazard ratio and Performance status.
His Colorectal cancer research is multidisciplinary, incorporating elements of Hyperthermic intraperitoneal chemotherapy, Cytoreductive surgery, Ex vivo, Cancer research and Tumor microenvironment.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
